San Francisco, 13 May 2019:
The global Gaucher Disease (GD) Drugs Market size is expected
to reach USD 1.71 billion by 2025, according to a new report by Grand View
Research, Inc., exhibiting a CAGR of 1.1% during the forecast period. Growing
prevalence of the disease and increasing research and development activities in
the field are likely to help the market in gaining momentum over the coming
years. With high unmet needs, there is a strong need for development of novel
treatments with improved efficacy in neuronopathic complications, convenient
dosage, and reduced cost.
Gaucher disease is a genetic
metabolic disorder, caused by mutations in GBA gene. People with Gaucher disease
produce low glucocerebrosidase (GCase), an enzyme required to degrade
glucocerebroside. Excess accumulation of lipids in spleen, liver, kidney,
brain, lungs, and bone marrow impedes the normal functioning of the organs.
In spite of being the most prevalent
lysosomal storage disorder, Gaucher disease is a rare condition with an average
prevalence of 1 in 100,000 individuals. However, certain ethnic races such as
Ashkenazi Jews are more susceptible to this disorder. Ashkenazi Jews have an
average disease prevalence of 1 in 500 individuals.
Currently, type 1 is the most common
form of Gaucher disease. This condition is nonneuronopathic in nature, as it
does not affect the central nervous system (CNS). Type 1 GD commanded more than
75.0% of the market in 2017. It is estimated to retain its position through
2025. Type 2 and type 3 are not as common as type 1.
On the basis of treatment, enzyme
replacement therapy (ERT) was the leading revenue contributor in the market in
2017. The growth of the segment can be attributed to strong sales of Cerezyme
and Vpriv. However, there has been an increase in inclination towards substrate
replacement therapy (SRT), spearheaded by Cerdelga and Zavesca. ERT is mostly
indicated for type 1 and type 3 (to address issues unrelated to the CNS), as
replacement enzymes cannot penetrate blood brain barrier. Additionally, there
is no effective treatment for type 2.
Access Research Report with TOC @ https://www.grandviewresearch.com/industry-analysis/gaucher-disease-drugs-market
Further key findings from the report suggest:
- Type 2 is the rarest of the three forms of GD, with average
mortality rate of less than two years
- Enzyme replacement therapy dominated the treatment landscape,
headed by Sanofi Genzyme’s Cerezyme. However, GD treatment is witnessing a
shift towards substrate replacement therapy, which is anticipated to
register a CAGR of over 7.5% during the forecast period
- The U.S. spearheaded the major markets, in terms of sales as well
as disease burden. The country will continue to dominate the market
through 2025, on account of widening patient base and easy accessibility
to treatments
- Some of prominent companies operating in the market are Sanofi
Genzyme, Shire, Pfizer, and Johnson & Johnson
- Sanofi Genzyme led the competitive space and is projected to
continue holding prominent position in the market over the coming years,
due to significant commercial performances of Cerezyme and Cerdelga
Grand View Research has segmented
the global Gaucher disease drugs market based on type, therapy, and country:
Gaucher Disease Drugs Type Outlook
(Revenue, USD Million, 2017 - 2025)
- Type 1
- Type 2
- Type 3
Gaucher Disease Drugs Therapy
Outlook (Revenue, USD Million, 2017 - 2025)
- Enzyme Replacement Therapy
- Substrate Replacement Therapy
Gaucher Disease Drugs Country
Outlook (Revenue, USD Million, 2017 - 2025)
- U.S.
- U.K.
- Germany
- Spain
- France
- Italy
- Japan
Access
Press Release of Gaucher
Disease Drugs Market @ https://www.grandviewresearch.com/press-release/global-gaucher-disease-drugs-market
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
For More
Information: www.grandviewresearch.com
No comments:
Post a Comment